Table 2.
Short-Term Cost-Savings with rtPA Treatment
| Outputs | rtPA | Placebo |
|---|---|---|
| Intracerebral hemorrhage events, N | 6.45 | 1.00 |
| Total QALYs, N | 225.16 | 179.85 |
| Total cost, $ | 8,872,933 | 9,225,364 |
| Additional intracerebral hemorrhage events, N | 5.45 | |
| QALYs gained, N | 45.31 | |
| Cost-Savings, $ | 352,430 | |
| Discounted outcomesa | ||
| Total discounted QALYs, N | 210.97 | 168.59 |
| Total discounted cost, $ | 8,651,313 | 8,996,752 |
| QALYs gained, N | 42.38 | |
| Cost-savings, $ | 345,438 | |
| Per patient | ||
| Quality-adjusted months gained, N | 5.1 | |
| Cost-savings, $ | 3454 | |
a
Discounts were made using the US Bureau of Labor Statistics. Consumer Price Index, Medical Care. Series ID, CUUR0000SAM2; not seasonally adjusted; area, US city average; item, medical care services; base period, 1982–1984 = 100. www.data.bls.gov/.
QALYs indicates quality-adjusted life-years; rtPA, recombinant tissue plasminogen activator.